Podcasts about cancer detection

In this episode of The Top Line, Fierce’s Chris Hayden speaks with Foresight Diagnostics co-founders Dr. Jake Chabon and Dr. Max Diehn about how their company is delivering the next generation of minimal residual disease (MRD) detection in cancer care. Born from research at Stanford University, Foresight’s PhasED-Seq technology delivers ultra-sensitive detection—down to parts per ten million—enabling clinicians to identify microscopic traces of cancer that traditional imaging misses. The discussion explores how Foresight’s MRD platform, CLARITY, can have the ability to support more confident decision-making, from determining curative success in early-stage cancers to guiding consolidation treatment in lymphoma. Chabon and Diehn highlight the company’s biopharma collaborations, clinical trial integration, and evidence-driven approach to guideline inclusion. They also look ahead to a future where MRD testing becomes central to oncology surveillance, accelerating therapy approvals and complementing genomic and digital pathology tools to advance precision medicine.See omnystudio.com/listener for privacy information.

Biochemist Lingyin Li survived breast cancer at just 30 and now works to harness the human immune system to fight cancers that have long evaded treatment. T cells, she says, are powerful cancer killers, but they can be oblivious. She and her lab colleagues have discovered a masking enzyme that squelches the immune system's “danger signals” and are now developing drugs to block that enzyme. She likens her work to an arms race between cancer and immunotherapy. “The cancers are not getting smarter, but we are,” Li tells host Russ Altman on this episode of Stanford Engineering's The Future of Everything podcast.Have a question for Russ? Send it our way in writing or via voice memo, and it might be featured on an upcoming episode. Please introduce yourself, let us know where you're listening from, and share your question. You can send questions to thefutureofeverything@stanford.edu.Episode Reference Links:Stanford Profile: Lingyin LiConnect With Us:Episode Transcripts >>> The Future of Everything WebsiteConnect with Russ >>> Threads / Bluesky / MastodonConnect with School of Engineering >>> Twitter/X / Instagram / LinkedIn / FacebookChapters:(00:00:00) IntroductionRuss Altman introduces guest Lingyin Li, a professor of biochemistry at Stanford University.(00:03:38) Research MotivationLingyin explains how her breast cancer diagnosis inspired her research.(00:04:31) How T-Cells WorkT-cell mechanisms and why they struggle to reach solid tumors.(00:05:38) Immune System OverviewInnate and adaptive immunity and how mutations make cancer recognizable.(00:07:28) Awakening the Immune SystemEfforts to stimulate innate immune cells to detect and expose tumors.(00:10:54) The Cancer SignalDiscovery of cancer-derived DNA signals that alert the immune system.(00:13:01) Cancer's Evasion MechanismHow tumors destroy immune signals to hide from detection.(00:14:26) ENPP1 EnzymeIdentification of ENPP1 as the enzyme enabling immune evasion.(00:15:22) Balancing Immunity and SafetyRole of ENPP1 in autoimmunity and the challenge of targeting it safely.(00:19:30) ENPP1 InhibitorsDevelopment of molecules to block ENPP1 and enhance immune signaling.(00:24:55) Preclinical FindingsThe promising results against aggressive solid tumors in animal studies(00:28:05) From Lab to ClinicThe progress toward FDA approval and preparation for human testing.(00:31:04) Future In a MinuteRapid-fire Q&A: innovation, collaboration, and the outlook for cancer treatment.(00:33:14) Conclusion Connect With Us:Episode Transcripts >>> The Future of Everything WebsiteConnect with Russ >>> Threads / Bluesky / MastodonConnect with School of Engineering >>>Twitter/X / Instagram / LinkedIn / Facebook Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Dr. Tomasz Beer, MD, chief medical officer at Exact Sciences, joins HealthLeaders for a discussion on the clinical research behind Cancerguard tests and how they enable health systems to detect multiple deadly cancers early, streamline diagnostic workflows, and deliver proactive, value-based care. Information presented is not clinical, diagnostic, or treatment advice for any particular patient. Providers should use their clinical judgement and experience when deciding how to diagnose or treat patients. Exact Sciences does not recommend or endorse any particular course of treatment or medical choice. The Cancerguard test was developed, and the performance characteristics validated by Exact Sciences Laboratories following College of American Pathologists (CAP) and Clinical Laboratory Improvement Amendments (CLIA) regulations. This test has not been cleared or approved by the US Food and Drug Administration. The test is performed at Exact Sciences Laboratories. Exact Sciences Laboratories is accredited by CAP, certified under CLIA regulations, and qualified to perform high-complexity clinical laboratory testing.

This Veterans Day, we're shining a light on care for those who've served.Dr. Elizabeth (Betsy) O'Donnell, Director of the Multi-Cancer Early Detection Clinic at Dana-Farber Cancer Institute, joins the PQI Podcast to discuss the Sentinel Study—a Department of Defense–sponsored clinical trial offering multi-cancer early detection (MCED) testing to U.S. veterans.Through a single blood draw, the test can screen for more than 50 types of cancer, addressing the urgent need for improved screening among veterans, who face a cancer risk nearly 20% higher than the general population.Dr. O'Donnell shares how this innovative study combines science, service, and compassion to bring life-saving research to those who've served—and what it could mean for the future of oncology care.Listen to learn more about:How early detection technology is transforming the future of cancer careWhy veterans face unique cancer risks linked to their serviceWhat makes the Sentinel Study a model for accessible, equitable screeningThe personal motivation that drives Dr. O'Donnell's workFor more information on the Sentinel study or to determine eligibility, visit redcap.link/VeteransScreeningStudy or contact the Sentinel Team at dfciprevention@mgb.org

Click here to view the full article on Oncology Data Advisor: https://oncdata.com/mary-pasquinelli-sybil-ai In this episode of Exploring AI in Oncology, Dr. Waqas Haque speaks with Mary Pasquinelli, DNP, Nurse Practitioner and Director of the Lung Screening Program at the University of Illinois (UI) Health, about the evolving role of screening and artificial intelligence (AI) in lung cancer detection. Their conversation spans program design, health equity, AI validation in diverse populations, multimodal detection with circulating tumor DNA (ctDNA) and imaging, and practical strategies that boost adherence and impact in both academic and community settings.

In this episode, let's talk with Dr Baboudjian, from Marseille, about the systematic biopsies.Discover:Is this the end of systematic biopsies?The rise of transperineal biopsiesPractice evolution still unevenHosted by Ausha. See ausha.co/privacy-policy for more information.

A new treatment for Type 1 diabetes that is expected to greatly reduce or eliminate the need for insulin; early cancer detection; fun historical tidbits about grooming, the development of daylight saving time, and past importance of handkerchiefs; and details about the upcoming Jackpot of Opportunities conference and convention of the Kentucky Council of the Blind. Find out more at https://sound-prints.pinecast.co

In this episode, we chat with Dr. Renee Goreham, a physicist and nanotechnologist at the University of Newcastle, and passionate science communicator. Renee is an experimental physicist exploring how our breath could hold the key to detecting lung cancer early—by identifying specific proteins as biomarkers. We also delve into her PhD student's exciting research into a new red-light laser diagnostic tool for breast cancer. Along the way, Renee breaks down the basics of cell biology and shares her inspiring, non-linear journey through physics, nanotech, and beyond. A brilliant example of multidisciplinary science in action. Follow Renee on TikTok: @dr_renee_goreham

On this episode of Impact Quantum, we dive into the visionary world of Sanjay Chittore, founder of Quantum AI Global and QLabs, who's on a mission to bring quantum theory out of the realm of science fiction and into real-world applications. Joined by host Frank La Vigne and the wonderfully quantum-curious Candice Gillhoolley, we unravel common myths about quantum computing—like whether you really need a quantum computer to build quantum products—and explore the massive impacts quantum technology is poised to have on everything from healthcare diagnostics to next-generation memory and sensing.Sanjay shares his journey from startup success through the pandemic to his self-driven deep dive into quantum and AI, revealing why he believes the future hinges on the synergy of quantum physics and electronics, rather than the traditional computing and electronics combination. Prepare to have your assumptions challenged as we discuss what makes quantum so secure, so fast, and so revolutionary—plus real-world examples like quantum memory, quantum sensors in healthcare, and the bold dreams that keep this field moving forward.Whether you're a scientist, entrepreneur, or just quantum-curious, this episode offers inspiring insights into how today's breakthroughs could transform industries and everyday life. Buckle up—things are about to get entangled!Time Stamps00:00 Quantum-AI Product Integration Company04:36 "AI Focus Led to Quantum"08:20 Quantum Discovery and Einstein's Doubts10:49 "Futuristic Startups: Embrace Risks"16:04 "Quantum Computers Lack Storage"19:15 "Quantum Sensors: Superior Precision"22:39 "Quantum Sensor for Cancer Detection"24:48 "Quantum Sensors and Cryptography"28:43 "Quantum: Infinite Between Ones, Zeros"31:50 "Unhackable Quantum Qubits Explained"34:52 "Solving Maze Navigation"38:38 "Quantum Efficiency Simplified"43:19 "Supporting PhDs in Industry"45:02 India's First Quantum Cryptography Product47:42 "Classical to Quantum Conversion"53:40 Quantum Revolution: Theory to Reality54:19 "Bailey's Quantum Farewell"

Blind biopsies leave questions unanswered. In this episode of BackTable OBGYN, host Dr. Mark Hoffman welcomes back Dr. Linda Bradley, an expert in obstetrics, gynecology, and hysteroscopy from the Cleveland Clinic, to discuss the benefits and advancements of direct visualized endometrial sampling over traditional blind biopsy techniques. ---This podcast is supported by:Medtronichttps://www.medtronic.com/en-us/healthcare-professionals/specialties/gynecology/product-portfolio.html---SYNPOSISDr. Bradley emphasizes the importance of hysteroscopy for accurate diagnosis and treatment of various gynecological issues, including abnormal uterine bleeding. They explore the limitations of blind biopsies and the advantages of hysteroscopy in detecting focal lesions, avoiding unnecessary hysterectomies, and ensuring patient safety. The discussion also touches on the economic and procedural challenges in adopting hysteroscopy more widely in clinical practice.---TIMESTAMPS00:00 - Introduction 03:30 - The Evolution of Hysteroscopy at Cleveland Clinic04:49 - Challenges and Innovations in Hysteroscopy06:30 - Clinical Insights: Direct Visualized Endometrial Sampling12:03 - Case Studies and Practical Applications15:46 - The Importance of Visual Examination in Gynecology20:03 - Advocating for Hysteroscopy in Medical Practice31:07 - Patient History and Trauma Considerations31:34 - Cancer Detection and Missed Diagnoses32:14 - Challenges with Unscheduled Bleeding32:56 - Case Study: Blood Transfusions and Hysterectomy33:38 - Importance of Hysteroscopy34:43 - Hysteroscopy Techniques and Best Practices37:41 - Ultrasound and SIS (Saline Infusion Sonohysterography) for Imaging38:45 - Post-Operative Care and Follow-Up47:41 - Environmental and Economic Considerations in Healthcare52:51 - Final Thoughts and Patient Advocacy

What if the future of cancer detection was just a simple blood test away? In this episode of the Women in Leadership Talk Podcast, host Vicki Bradley sits down with Susan Tousi, CEO of DELFI Diagnostics, to explore how she's leading the charge in life sciences with groundbreaking approaches to early cancer detection.Susan shares her journey from corporate leadership to startup CEO, the role of AI in advancing healthcare, and the importance of self-belief when taking bold career leaps. She also opens up about work-life balance, resilience, and why having a strong support system can empower women to lead with confidence.Want to deepen your leadership journey?You'll find two FREE mini-courses designed to elevate your leadership skills and a powerful leadership quiz to help you understand how you show up in the world, personally and professionally. Explore now: www.wilempowered.com, www.wilempowered.com/free-mini-course/ 

Guest: Jennifer Caudle, DO Host: Patrick McGill, MD Current cancer screening guidelines cover just five cancers—breast, lung, colon, prostate, and cervical—leaving many aggressive cancers undetected until later stages. But multi-cancer early detection (MCED) testing is reshaping the landscape with blood-based analyses of cell-free DNA and methylation patterns to identify potential cancers earlier than traditional imaging. Designed for the general population over age 50, MCED testing complements rather than replaces standard screenings, helping detect cancers at stages when treatment is most effective. Joining Dr. Jennifer Caudle to share practical strategies for integrating MCED into clinical workflows, addressing misconceptions, and streamlining follow-up protocols is Dr. Patrick McGill, board-certified family physician and Executive Vice President, Chief Transformation Officer at Community Health Network in Indianapolis.

Clarence Ford spoke to Kresantha Pillay, Chief Specialist: Lifestyle Protector about cancer detection trends among South Africans. Views and News with Clarence Ford is the mid-morning show on CapeTalk. This 3-hour long programme shares and reflects a broad array of perspectives. It is inspirational, passionate and positive. Host Clarence Ford’s gentle curiosity and dapper demeanour leave listeners feeling motivated and empowered. Known for his love of jazz and golf, Clarrie covers a range of themes including relationships, heritage and philosophy. Popular segments include Barbs’ Wire at 9:30am (Mon-Thurs) and The Naked Scientist at 9:30 on Fridays. Thank you for listening to a podcast from Views & News with Clarence Ford Listen live on Primedia+ weekdays between 09:00 and 12:00 (SA Time) to Views and News with Clarence Ford broadcast on CapeTalk https://buff.ly/NnFM3Nk For more from the show go to https://buff.ly/erjiQj2 or find all the catch-up podcasts here https://buff.ly/BdpaXRn Subscribe to the CapeTalk Daily and Weekly Newsletters https://buff.ly/sbvVZD5 Follow us on social media: CapeTalk on Facebook: https://www.facebook.com/CapeTalk CapeTalk on TikTok: https://www.tiktok.com/@capetalk CapeTalk on Instagram: https://www.instagram.com/ CapeTalk on X: https://x.com/CapeTalk CapeTalk on YouTube: https://www.youtube.com/@CapeTalk567 See omnystudio.com/listener for privacy information.

In this episode, CANCER BUZZ speaks with Bart Daugherty, vice president of clinical technology and systems at Georgetown Cancer Center, Lifepoint Health, about his program's receipt of a 2025 ACCC Innovator Award. Lifepoint's innovation, Transforming Cancer Detection and Treatment with the AI-Driven Healthy Person Program, leverages artificial intelligence (AI) to analyze the health records of all patients who have received care at Lifepoint Health's facilities and identify those who are at risk of developing catastrophic diseases. This initiative, dubbed the Healthy Person Program, has already impacted over 280,000 patients since the deployment of Lifepoint's AI tool and made significant strides in improving population health in its communities.    Bart Daugherty Vice President, Clinical Technology and Systems Lifepoint Health Brentwood, Tennessee    “We've taken a lot of the administrative burden off of [our cancer team] and allowed them to focus on critical patient [cases].”  – Bart Daugherty    This podcast is part of a special series featuring the 2025 ACCC Innovator Award winners. For a deeper dive into this topic and other content that will help your team reimagine how care is delivered at your cancer program or practice, register today for the ACCC 42nd National Oncology Conference, October 15-17 in Denver, Colorado.    Resources:  Cancer Crushing Prevention and Early Detection  ACCC Recognizes National Cancer Prevention and Early Detection Month  Exploring Current Perceptions of Multi-Cancer Early Detection Testing Among Healthcare Providers  [PODCAST] Ep 05: Rural Cancer Care 

A large observational study found small but potentially meaningful differences in cardiovascular safety among sulfonylureas compared to DPP-4 inhibitors in type 2 diabetes, with glipizide showing a statistically higher risk of MACE. A separate study revealed that over half of advanced-stage lung and colorectal cancer cases involved missed diagnostic opportunities, highlighting systemic delays in workups and follow-up. Finally, the EchoNext deep learning model accurately predicted structural heart disease from ECG data alone, outperforming cardiologists and showing potential for scalable, cost-effective screening. These findings underscore the importance of individualized treatment, earlier cancer detection, and AI-enabled cardiac diagnostics.

Early cancer detection doesn't have to mean invasive tests. In this podcast episode, we sit down with Jeff Bousfield, CEO of Nonacus Cancer Diagnostics, to explore how his UK-based company is revolutionizing precision cancer diagnostics with a powerful suite of non-invasive tools. Jeff shares the human story behind the science and why he believes the future of cancer care starts with precision diagnostics tools that are faster, less invasive, and more accessible to patients.

DermaSensor has developed the first FDA-cleared, AI-powered skin cancer detection device specifically designed for primary care physicians. After spending $27 million on R&D over eight years and conducting 15 clinical studies, the company received FDA clearance in January 2024. Using elastic scattering spectroscopy, the device analyzes cellular and subcellular structures in skin tissue—the same characteristics pathologists examine under microscopes—to provide objective skin cancer risk assessments in under 30 seconds. In this episode, CEO Cody Simmons shares the journey from Boston University research lab to commercial deployment across hundreds of medical practices. Topics Discussed: DermaSensor's eight-year development journey from 30-pound research devices to handheld commercial products The FDA clearance process requiring five pre-submission meetings and over 10,000 pages of documentation Strategic decision to target primary care physicians rather than dermatologists based on competitive intelligence Clinical validation showing device accuracy matches in-person dermatologist assessments Commercial launch strategy achieving coverage from major media outlets without a major PR firm Rapid adoption by hundreds of private practices within the first year post-clearance GTM Lessons For B2B Founders: Learn from competitive failures before choosing your market: Cody observed companies spending "literally hundreds of millions of dollars" targeting dermatologists with similar devices, only to see them "commercially immediately fizzled out" within 2-4 years. Dermatologists, being experts, were confident in their existing processes and questioned why they needed additional tools. This competitive intelligence led DermaSensor to target primary care physicians who welcomed objective second opinions. B2B founders should study why similar solutions failed in adjacent markets and identify underserved segments where their value proposition resonates more strongly. Align your commercial strategy with regulatory requirements years in advance: Cody emphasized that you must "align your plan like your commercial plan with your study" and your FDA indication for use, determining "who's actually approved to use the device for what purpose." This planning must happen years before approval since clinical studies are designed around the intended commercial application. B2B founders in regulated industries should work backwards from their go-to-market strategy when designing regulatory pathways, ensuring clinical evidence supports their target market and use cases. FDA clearance itself can be your biggest PR moment: DermaSensor achieved coverage on ABC, NBC, CBS, Fox, Forbes, Reuters, and Time Magazine's Best Inventions list primarily because "the FDA clearance itself was so big" for a first-in-class device addressing "the most common cancer." They worked with only an independent PR consultant, not a major firm. B2B founders should recognize that major regulatory milestones, especially for novel technologies, inherently generate media interest and plan their launch communications accordingly. Prioritize speed and simplicity when displacing manual processes: The device works in "less than 30 seconds" from pickup to result, addressing primary care physicians who previously had to rely on visual assessment with minimal dermatology training (only "two to four hours of training in medical school"). The combination of speed, objectivity, and ease of use made adoption attractive to non-specialists. B2B founders should design solutions that are dramatically faster and more accurate than existing manual processes, especially when targeting users who lack specialized expertise. Private practices adopt faster than health systems but both are essential: Cody noted that "private practices, because they make decisions so quickly" with "one or two doctors that run the practice" were able to rapidly adopt the technology. However, health systems provide validation and scale. The company focused on building "that whole ecosystem" where "health systems using a private practice, using it. Dermatologists are aware of it." B2B founders should sequence their go-to-market to capture quick wins from agile smaller customers while simultaneously pursuing enterprise accounts for long-term growth and market credibility.   //   Sponsors: Front Lines — We help B2B tech companies launch, manage, and grow podcasts that drive demand, awareness, and thought leadership. www.FrontLines.io The Global Talent Co. — We help tech startups find, vet, hire, pay, and retain amazing marketing talent that costs 50-70% less than the US & Europe.  www.GlobalTalent.co   //   Don't Miss: New Podcast Series — How I Hire Senior GTM leaders share the tactical hiring frameworks they use to build winning revenue teams. Hosted by Andy Mowat, who scaled 4 unicorns from $10M to $100M+ ARR and launched Whispered to help executives find their next role. Subscribe here: https://open.spotify.com/show/53yCHlPfLSMFimtv0riPyM 

Which brand of fish oil do you recommend lately?What supplements can help with ankle pain, specifically perineal tendonitis?Aren't doctors opening themselves up to a lawsuit by not using superior methods of cancer detection?Would magnesium help for atrial fibrillation caused by a heart valve replacement? What do you recommend for severe rheumatoid arthritis?How far apart should I eat any dairy from blueberries so as not to inhibit nutrient absorption?

The big C word- Cancer. It's a scary word to hear and nobody wants to receive the news. Unfortunately, 12 million dogs and cats are diagnosed with cancer each year and Moose's March wants to do something about it. From early cancer detection kits to approved products that can help with the fight against cancer, this organization is doing cool things.

This week: Why your gaze can boost running performance, a breakthrough in early cancer detection, the future of dental implants, and how childhood nutrition shapes adult health. Learn More: https://radiohealthjournal.org/run-faster-cancer-detection-high-tech-teeth/ Learn more about your ad choices. Visit megaphone.fm/adchoices

AI-boost for mammograms—a bridge too far? Plastics and heart disease; What does a high CRP mean? Social media marketing of female aphrodisiac dinged with FDA warning; Roundup gets a makeover; Artificial sweeteners may hasten puberty in kids; Plus an encore of our interview with Dr. Jeffrey Bland introducing Himalayan Tartary Buckwheat as a hedge against age-related immune decline.

Why rely on one method when three are better? Ezra CEO Emi Gal explains how combining imaging, liquid biopsy, and biomarkers creates a superior cancer screening protocol. He also shares how AI enables longitudinal tracking of lesions, reducing false positives and patient anxiety. Learn what makes Ezra's approach uniquely effective in the fight against cancer.

For years, China's cancer screening and survival rates have trailed behind those of developed nations. But 2025 could change everything. A breakthrough AI system named GRAPE is now helping Chinese hospitals detect stomach cancer earlier—with 20 percent higher accuracy than human doctors. No tubes, no discomfort—just a quick scan. Could this be the start of AI saving millions of lives? On the show: Heyang, Steve Hatherly & Yushan

(3:08) - A Sweet Solution for Safer Diagnosis and TreatmentThis episode was brought to you by Mouser, our favorite place to get electronics parts for any project, whether it be a hobby at home or a prototype for work. Click HERE to learn more about the use cases of human machine integration, where the technology is at today, and what the future holds! Become a founding reader of our newsletter: http://read.thenextbyte.com/ As always, you can find these and other interesting & impactful engineering articles on Wevolver.com.

This week we discussed Iran & Israel War, Quantum Computing, Cancer Detection,Benefit of Shaking Ears, Accountants in Kiev Ukraine and more #awakening #iran #quantumcomputing About my Co-Host:Arnold Beekes Innovator, certified coach & trainer and generalist. First 20 years in technology and organizational leadership, then 20 years in psychology and personal leadership (all are crucial for innovation).============What we Discussed: 00:00 What we are discussing in this weeks show 01:40 Iran and Israel War04:45 29 Countries do not Recognise Israel09:00 Humanoid Robiotics is going to be massive11:30 The WHO Pandemic Agreement13:40 Anti Immegrant Protests in Northern Ireland14:40 How to Stop the Illegal Immegration16:20 Meta AI New Model and Flying Cars19:00 Eventually Ai will be able to do all that humans can do 21:35 Larry Elison wants all Governements to share information for Ai24:20 Quantum Computing27:10 Prosthetic leg made for friend 31:15 John Hopkins Can detect Cancer 3 years before other methods detect it33:10 Clean Hydrogen Fuel from Soda Cans35:10 Dangers of Car Air Freshners37:40 Benefits of Yoga Nidra39:40 Benefits of Shaking Ears43:35 The Benefits of Ginger45:50 The Dangers of Bovaer49:20 The attack on the Farmers50:40 Obeying Orders not good for you55:50 The Constant Spraying in Lodz, Poland57:10 The Shield Protecting Children in the UK58:40 Accountants in Kiev, Ukraine ====================How to Contact Arnold Beekes: https://braingym.fitness/ https://www.linkedin.com/in/arnoldbeekes/===============Donations ⁠⁠ https://www.podpage.com/speaking-podcast/support/ ⁠⁠------------------All about Roy / Brain Gym & Virtual Assistants athttps://roycoughlan.com/------------------

AGNTCY - Unlock agents at scale with an open Internet of Agents. Visit https://agntcy.org/ and add your support. What if your blood could reveal the future of your health - years before symptoms ever appear? In this episode of Eye on AI, Craig Smith sits down with Ash Anwar, co-founder of Molecular You, to explore how AI and advanced biomarker analysis are transforming how we detect and prevent disease.  From a real-life case where stage 1 pancreatic cancer was caught early, to the science behind tracking 250+ dynamic biomarkers, Ash breaks down how Molecular You is shifting healthcare from reactive treatment to proactive longevity.  They dive into the limitations of genetic testing, the power of machine learning models trained on clinical data, and how personalized action plans are helping individuals take control of their health in real time.  If you're curious about the intersection of AI, diagnostics, and the future of preventive medicine—this is a conversation you won't want to miss. Stay Updated: Craig Smith on X: https://x.com/craigss Eye on A.I. on X: https://x.com/EyeOn_AI (00:00) How AI Can Predict Disease Before It Happens   (02:02) Meet Ash Anwar: From Scientist to Health Tech Leader   (06:31) What Is Molecular You and How It Works   (09:43) Why Biomarker Tracking Over Time Is a Game-Changer   (15:46) How Molecular You Detected Stage 1 Pancreatic Cancer   (23:15) Biomarkers vs Genetics: What Really Matters   (28:11) The AI Models Behind Early Disease Detection   (32:37) How the Product Works for Clinics and Consumers   (35:05) Who They Compete With and What Makes Them Different   (37:34) Research vs Product: The Cancer Risk Challenge   (43:43) How Often Should You Get Tested?

Is your business ready for the next wave of AI — or about to be eaten by it?In this week's episode of The Leveraging AI Podcast, Isar Meitis breaks down the latest tectonic shifts in the AI landscape. From OpenAI's aggressive move into enterprise applications to self-improving AI models and FDA-approved cancer detection tools, this isn't just another week in tech — it's a glimpse into the near future of business.AI is no longer just evolving — it's learning how to evolve itself. That means faster innovation, deeper disruption, and greater opportunity for those paying attention. So if you're leading a company, making decisions, or just trying to stay ahead — you can't afford to miss this.Recommendation: If you're relying on dashboards and human analysts alone, it's time to consider the AI layer that's changing enterprise strategy across industries.In this session, you'll discover:Why OpenAI's enterprise push is terrifying startups — and possibly Google and MicrosoftHow Databricks and Snowflake are redefining BI with "systems of intelligence"What Mary Meeker's AI mega-report says about tech acceleration — and what's not acceleratingWhich AI model is rewriting its own code (yes, you read that right)How AI just helped the FDA approve a tool for early breast cancer detectionWhy layoffs tied to AI aren't slowing down — and why most leaders are still underestimating the shiftWhat's brewing at Microsoft, Meta, Apple, and Anthropic in the battle for enterprise dominanceHow new AI agents may eliminate the need for ad agencies and call centersAbout Leveraging AI The Ultimate AI Course for Business People: https://multiplai.ai/ai-course/ YouTube Full Episodes: https://www.youtube.com/@Multiplai_AI/ Connect with Isar Meitis: https://www.linkedin.com/in/isarmeitis/ Join our Live Sessions, AI Hangouts and newsletter: https://services.multiplai.ai/events If you've enjoyed or benefited from some of the insights of this episode, leave us a five-star review on your favorite podcast platform, and let us know what you learned, found helpful, or liked most about this show!

President Biden was recently diagnosed with an aggressive form of prostate cancer. We spend some time with Dr. Lucio Miele from LSU Health New Orleans about we know about prostate cancer, treatments, and how it can be caught.

AGNTCY - Unlock agents at scale with an open Internet of Agents. Visit https://agntcy.org/ and add your support.   What if AI could predict exactly when you'd get sick—and help you prevent it?   In this episode of Eye on AI, Dr. Eric Topol, world-renowned cardiologist, author, and AI health pioneer, joins us to unveil the future of preventive medicine. We dive deep into the themes of his new book Super Agers, which lays out a groundbreaking blueprint for extending healthspan—not just lifespan—through the power of multimodal AI and deep biological data.   Dr. Topol explains how AI models can now analyze a full-stack of human data—genomics, proteomics, metabolomics, microbiome, and more—to forecast age-related diseases like cancer, Alzheimer's, and heart disease decades before symptoms appear. This isn't science fiction. It's here now.   If you're interested in the intersection of AI, longevity, and the future of medicine, this is a must-listen.   Where AI Works tackles the big questions shaping AI's role in business today, cutting through the hype to deliver actionable insights for leaders. Brought to you by the Wharton School, in collaboration with Accenture, this podcast combines cutting-edge research with real-world case studies to uncover how top companies are using AI to upskill workforces, enhance customer experiences, boost productivity, and streamline operations.  Check it out:  https://link.cohostpodcasting.com/f5e223b4-da0c-4fc8-bbf3-5f24c15f8fd2?d=sxo9xhJN2    Stay Updated: Craig Smith on X:https://x.com/craigss Eye on A.I. on X: https://x.com/EyeOn_AI (00:00) The Power of Precision Medical Forecasting (01:53) Eric Topol's Journey into Digital & AI Medicine (03:27) Using AI to Prevent Aging-Related Diseases (05:25) The Challenge of Health Data Privacy & Ownership (09:05) Genetic Risk to Deep Data Insights (11:20) Personalized Prevention Through Lifestyle & Biomarkers (13:59) Why Anti-Aging Drugs Are Still Years Away (16:18) What are Organ Clocks (19:34) The Longevity Industry's Flawed Use of AI (21:59) Top AI Pioneers Endorse “Super Agers” (24:21) Which Longevity Startups Are Getting It Right? (26:27) Why Topol Refuses to Join Longevity Startups (28:57) Topol's Own Health Data & Lessons Learned (30:25) How Accurate Is AI at Predicting Disease Timing? (31:47) The Truth About Genetic Risk and Cancer Detection (33:33) AI-Driven Cancer Detection: A Smarter Approach (38:51) How Precision Medicine Has Evolved (41:02) The Risky Reality of Anti-Aging Interventions (44:39) Why Healthspan Matters More Than Lifespan

Navigating the intricate landscape of medical technology often involves overcoming substantial challenges, not just in device innovation but also in ensuring successful integration into healthcare systems. One significant hurdle is the adoption of new technologies by general practitioners, who require tools that are both effective and easy to integrate into their existing workflows without the complexities of specialist equipment. In this week's episode, sponsored by Physician Growth Accelerator, we are joined by Cody Simmons, co-founder and CEO of DermaSensor. Cody discusses DermaSensor, a revolutionary device that simplifies skin cancer detection, enabling general practitioners to diagnose with the accuracy of dermatologists. We delve into the story of DermaSensor, from its initial conception to achieving FDA clearance and the challenges faced in bringing this innovative technology to market. What we discuss in the episode: The development of DermaSensor and its impact on simplifying skin cancer detection for non-specialists. The barriers to technology adoption in healthcare, particularly issues around reimbursement and system integration. Strategies employed by DermaSensor to navigate regulatory hurdles and market challenges. Real-world benefits of the device in improving diagnostic accuracy and reducing healthcare inefficiencies. Resources from this episode:  Get the free MedTech Talk Tracks for Action Physician Growth Accelerator DermaSensor Social Media:  Connect with Cody on LinkedIn Connect with Zed on LinkedIn

In this episode of Menopause Mastery, I sit down with Sumit Rai, founder of Cancer Check Labs, to uncover a groundbreaking new approach to cancer screening and prevention. We dive deep into how cancer really develops—years before it's detectable by traditional scans—and why early detection at the cellular level could be the key to saving millions of lives. Sumit shares the powerful story behind his mission, the hidden dangers accelerating cancer rates (including toxins, diet, and lifestyle), and how standard treatments like chemo and surgery often miss the bigger picture. We also explore his revolutionary blood test that can find cancer cells before tumors become visible—and how new technologies like blood filtration could transform cancer care forever. If you're serious about proactive health, longevity, and protecting yourself and your loved ones, this is a must-listen conversation packed with science, hope, and action steps you can take today.  

In this episode of the Exploring AI in Oncology podcast, Waqas Haque, MD, MPH, a Hematology/Oncology Fellow at the University of Chicago, speaks with Samir Shah, MD, MMM, FACR, the Chief Medical Officer at Qure.ai. Their discussion explores how Qure.ai's innovative AI solutions are addressing critical gaps in lung cancer screening and improving early detection through advanced image analysis and clinical data integration.

Atzeyo Biosensors' platform helps doctors diagnose cancer in their offices.

Finding the right treatment for cancer is difficult at times, so how can computing power help us with this goal? Gabe Kwong, the Robert A. Milton associate professor of biomedical engineering at Georgia Tech University, examines. Gabe A. Kwong, Ph.D. is the Robert A. Milton Endowed Chair and Associate Professor of Biomedical Engineering at Georgia […]

BUFFALO, NY - April 8, 2025 – A new #editorial was #published in Oncotarget, Volume 16, on April 4, 2025, titled “Deep learning-based uncertainty quantification for quality assurance in hepatobiliary imaging-based techniques." Dr. Yashbir Singh from Mayo Clinic and his colleagues discussed how artificial intelligence (AI) can improve liver imaging by recognizing when it might be wrong. This approach, called “uncertainty quantification,” helps clinicians better detect liver cancer and other diseases by pointing out areas in medical scans that need a second look. The authors explain how these AI tools could make imaging results more accurate and reliable, which is especially important when diagnosing serious conditions like liver tumors. Liver and bile duct imaging is difficult because of the organ's complex structure and differences in image quality. Even skilled radiologists can struggle to identify small or hidden tumors, especially in patients with liver damage or scarring. The editorial explains how new AI models not only read medical images but also measure their own confidence. When the AI system is unsure, it can alert clinicians to take a closer look. This extra layer of information can reduce missed diagnoses and improve early detection of liver cancer. One of the most advanced tools described in the editorial is called AHUNet (Anisotropic Hybrid Network). This AI model works with both 2D and 3D images and can highlight which parts of a scan it is most confident about. It performed well when measuring the entire liver and showed how its confidence dropped when scanning smaller or multiple lesions. This feature helps clinicians know when more testing or review is needed. The authors also looked at other AI models used in liver imaging. Some tools were able to analyze liver fat using ultrasound images and give clinicians both a result and a confidence score. Others improved the speed and accuracy of liver magnetic resonance imaging (MRI) scans, helping to create clear images in less time. These advancements could help hospitals work faster and provide better care. The editorial highlights how this technology can be especially helpful in smaller clinics. If they do not have liver specialists, they could still use AI systems that flag uncertain results and send them to larger centers for review. Such an approach could improve care in rural or less-resourced areas. “Radiology departments should develop standardized reporting templates that incorporate uncertainty metrics alongside traditional imaging findings.” By using AI tools that know when to second-guess themselves, clinicians may soon have more reliable methods for detecting liver cancer and monitoring liver disease. The authors suggest that uncertainty-aware AI may soon become a vital part of everyday medical imaging, supporting faster and more accurate decisions in liver disease care. DOI: https://doi.org/10.18632/oncotarget.28709 Correspondence to: Yashbir Singh — singh.yashbir@mayo.edu Video short - https://www.youtube.com/watch?v=Zm0QASQ_YSI Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28709 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords: cancer, deep learning, uncertainty quantification, radiology, hepatobiliary imaging To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957

In the wake of Atlantic editor-in-chief Jeffrey Goldberg's accidental inclusion in senior government officials' Signal group chat discussing war plans, Reid weighs in on how the U.S. government should—and shouldn't—use encrypted messaging apps. He and Aria also discuss AI-powered breakthroughs in cancer detection and medical diagnostics, along with NVIDIA's newly announced Superchip and OpenAI's latest image generation capabilities.  For more info on the podcast and transcripts of all the episodes, visit https://www.possible.fm/podcast/ 

Lung cancer is on the rise, even among those who have never smoked. Dr. Stephen Lam is a respirologist with the BC Cancer Research Centre, and has dedicated his career to lung cancer research and early detection. Stephen dives into the role of AI in predicting lung cancer risk and practical strategies to safeguard your lungs.

Physician Ash Alizadeh has seen the future of disease diagnosis and monitoring. It is coursing through every patient's veins. Traditionally, biopsies have required invasively gathering tissue – from a lung, a liver, or a fetus. Now it's possible to look for disease without surgery. The DNA is sitting there in the bloodstream, Alizadeh tells host Russ Altman, as they preview the age of liquid biopsies on this episode of Stanford Engineering's The Future of Everything podcast.Have a question for Russ? Send it our way in writing or via voice memo, and it might be featured on an upcoming episode. Please introduce yourself, let us know where you're listening from, and share your quest. You can send questions to thefutureofeverything@stanford.edu.Episode Reference Links:Stanford Profile: Ash A. Alizadeh, MD/PhDConnect With Us:Episode Transcripts >>> The Future of Everything WebsiteConnect with Russ >>> Threads / Bluesky / MastodonConnect with School of Engineering >>> Twitter/X / Instagram / LinkedIn / FacebookChapters:(00:00:00) IntroductionRuss Altman introduces guest Ash Alizadeh, a faculty member at Stanford University in Oncology and Medicine.(00:03:39) What is a Liquid Biopsy?Accessing tissues non-invasively using bodily fluids.(00:04:31) Detecting Cancer with Liquid BiopsiesHow localized cancers can be detected through blood samples.(00:06:32) The Science Behind Cancer DNA DetectionThe differences between normal and cancer DNA(00:09:51) How Liquid Biopsy Technology WorksThe technologies behind detecting cancer-related DNA differences.(00:12:36) Advances in Liquid BiopsyNew detection approaches using non-mutant molecules and RNA.(00:14:10) RNA as a Real-Time Tumor MarkerHow RNA reveals active tumor processes and drug resistance.(00:15:55) Tracking Cancer ReccurenceUsing tumor-informed panels to monitor cancer recurrence.(00:16:28)  Adapting to Tumor EvolutionWhy core mutations remain detectable despite cancer changes.(00:17:57) Stability of DNA, RNA, and MethylationComparing durability and reliability of different biomarkers.(00:20:49) Listener Question: Early Cancer DetectionDaniel Kim asks about pre-cancer detection and its potential impact.(00:24:44) Liquid Biopsy in ImmunotherapyUsing liquid biopsy to track and improve immune-based treatments.(00:27:35) Monitoring CAR T-Cell TherapyHow liquid biopsy helps assess immune cell expansion.(00:32:02) EPIC-Seq: Inferring RNA from DNAUsing DNA fragmentation to predict gene expression in tumors.(00:34:49) Targeting Tumor Support SystemsTreatment strategies disrupting the tumor microenvironment.(00:35:52) Conclusion Connect With Us:Episode Transcripts >>> The Future of Everything WebsiteConnect with Russ >>> Threads / Bluesky / MastodonConnect with School of Engineering >>>Twitter/X / Instagram / LinkedIn / Facebook

What if you could take control of your health and add years to your life? In this episode of Next Steps 4 Seniors: Conversations on Aging, Wendy Jones sits down with Dr. John Calado to uncover the secrets to longevity, early detection, and proactive health measures that can make all the difference.

Join us as we review recent articles and news featured in The DIGEST issues #59-61, including cfDNA and incidental detection of cancer in pregnancy, vitamin K2 for nocturnal leg cramps, the danger of as-needed anti-hypertensive medications in the hospital, GLP-1 agonists for alcohol use disorder, short-course (7 vs 14 days) antibiotics for bacteremia, and patient-collected HPV testing for cervical cancer screening. Fill your brain hole with a fully digestible meal! Featuring Laura Glick MD, Nora Taranto (@norataranto), Paul Williams (@paulnwilliamz), and Matt Watto (@doctorwatto).  Claim CME for this episode at curbsiders.vcuhealth.org! Patreon | Episodes | Subscribe | Spotify | YouTube | Newsletter | Contact | Swag! | CME Show Segments 00:00 Introduction and Overview 02:57 The IDENTIFY study: Non-Invasive Prenatal Testing and Cancer Detection with cfDNA 05:54 Implications of Non-Reportable Results in Prenatal Testing 08:51 Vitamin K2: A New Approach to Managing Nocturnal Leg Cramps 12:07 Practicality and Future of Vitamin K2 in Clinical Practice 23:21 The Dangers of As-Needed Antihypertensives in the hospital 32:21 Exploring GLP-1 Agonists for Alcohol Use Disorder 40:24 Shorter Antibiotic Courses in Sepsis 46:09 Advancements in Patient-Collected HPV Screening for cervical cancer Credits Written and Produced by: Nora Taranto MD, Laura Glick MD, Matthew Watto MD, FACP; Paul Williams MD, FACP Show Notes: Nora Taranto MD Cover Art: Matthew Watto MD, FACP Hosts: Nora Taranto MD, Laura Glick MD, Matthew Watto MD, FACP; Paul Williams MD, FACP    Reviewer: Emi Okamoto MD Showrunners: Matthew Watto MD, FACP; Paul Williams MD, FACP Technical Production: PodPaste Disclosures The Curbsiders report no relevant financial disclosures.  Sponsor: Bombas Head over to Bombas.com/curb and use code curb for 20% off your first purchase. Sponsor: Pretty Litter  Go to PrettyLitter.com/curb to save twenty percent on your FIRST order and get a free cat toy.  Sponsor: Rocket Money  Cancel your unwanted subscriptions and reach your financial goals faster with Rocket Money. Go to RocketMoney.com/CURB today.

Dr. Raz joins Dorothy Gibbons to discuss the increasing incidence of breast cancer in women under 40 and the challenges of early detection. He explains that improved screening technology and methodologies are revealing more cases and emphasizes the need for nuanced risk stratification models to identify higher-risk women earlier. Key Questions Answered 1. Has cancer increased in younger women? 2. What does incidence refer to? 3. Why might the incidence of cancer be increasing? 4. Would changing the screening age for cancer be beneficial? 5. How could screening methodologies be improved? 6. Why is it challenging to determine an appropriate screening age? 7. How does race and socioeconomic status affect cancer detection and outcomes? 8. What tools or models can help in risk stratification for breast cancer? 9. Why is a consensus from national bodies necessary for changing screening guidelines? 10. What advancements in breast cancer screening are promising? Timestamped Overview 00:00 Rising Cancer Detection Rates 03:23 Rising Breast Cancer Risks in Women 09:26 MRI Advancements and Cancer Detection 12:41 Ultrasound Enhances Cancer Detection 14:25 Distinct Cancer Pathology in Screenings 16:26 Peripartum Cancer Detection Challenges Subscribe to Let’s Talk About Your Breasts on Apple Podcasts, Spotify, iHeart, and wherever you get your podcasts.See omnystudio.com/listener for privacy information.

In this episode, Dr. Shawn Tassone discusses various aspects of hormone health, particularly focusing on breast cancer screening methods including mammography, ultrasound, and thermography. He shares insights from his book, 'The Hormone Balance Bible', and emphasizes the importance of understanding different testing methods, their pros and cons, and emerging technologies in breast imaging. The conversation aims to empower women with knowledge about their health and the options available for cancer detection and prevention. Episode Highlights: The Hormone Balance Bible provides insights into hormone imbalances. Mammography, ultrasound, and thermography are key breast cancer screening methods. Each screening method has its own pros and cons. Thermography is a physiological test, while mammography and ultrasound are structural tests. Mammograms can miss fast-growing tumors due to their nature. Ultrasound can detect some tumors missed by mammograms. Thermography has a lower false positive rate compared to mammograms and ultrasounds. Emerging technologies like the QT scan may offer new options for breast imaging. Prevention is more important than detection in cancer care. Women should choose the screening method that resonates with them.  

Louie Helmecki shares his deeply personal journey through multiple cancer diagnoses, shedding light on the emotional, physical, and medical challenges he faced along the way. From enduring chemotherapy and surgeries to navigating the complexities of cancer recurrence, Louie speaks candidly about the toll of treatment and the resilience required to push forward. He and Freddie Kimmel discuss the critical role of health ownership, the importance of advocating for the right medical care, and the gaps in traditional medicine that often leave patients searching for more holistic solutions. Louie's story is not just about surviving but about reclaiming control over his well-being and redefining what it means to thrive beyond cancer. This conversation also delves into groundbreaking health innovations, including the use of peptides, GLP-1 medications, and lifestyle medicine as tools for recovery and disease prevention. Freddie and Louie explore the latest advancements in cancer detection, weight management, and muscle preservation, emphasizing the importance of a personalized and proactive approach to health. They highlight the growing integration of complementary therapies like red light therapy, IV treatments, and biohacking strategies that support the body's natural healing process. More than just a story of struggle, this episode is a testament to the power of mindset, education, and taking action to build a life beyond illness.Chapters00:00 Introduction to Cancer Journeys05:00 Louie's Cancer Diagnosis and Initial Treatment09:52 Chemotherapy Experiences and Challenges16:01 Surgery and Recovery Insights20:01 Recurrence and New Diagnosis30:00 Navigating Medical Decisions and Expert Opinions35:50 Navigating Cancer Treatment Experiences41:07 The Intersection of Traditional and Complementary Medicine49:01 Innovations in Health and Wellness Practices55:46 Understanding Peptides and Their Impact on Health01:05:59 Exploring Weight Loss Medications01:08:02 The Importance of Comprehensive Health Assessments01:09:55 Navigating Weight Loss Programs Responsibly01:12:03 Innovative Approaches to Health and Wellness01:16:52 Cancer Detection and Preventative Measures01:26:51 Life Lessons from Cancer SurvivalUPGRADE YOUR WELLNESSSilver Biotics Wound Healing Gel: https://bit.ly/3JnxyDD (30% off)Code: BEAUTIFULLYBROKENSaga Bands: https://ca.saga.fitness/?ref=titvyccmCode: beautifullybrokenStemRegen: https://www.stemregen.co/products/stemregen?_ef_transaction_id=&oid=1&affid=52Code: beautifullybrokenLightPathLED https://lightpathled.pxf.io/c/3438432/2059835/25794Code: beautifullybroken CONNECT WITH FREDDIE Check out my website and store: (http://www.beautifullybroken.world) Instagram: (https://www.instagram.com/beautifullybroken.world/) YouTube: (https://www.youtube.com/@BeautifullyBrokenWorld)

Today I'm speaking with Dr. Paziotopoulos on the Longevity Optimization Podcast. In this episode, we explore his unique journey into the field of medicine and longevity, focusing on the integration of AI in health monitoring and the innovative concept of medical maintenance engineering. The conversation delves into the importance of imaging, the role of supplements, and the critical significance of compliance in health programs. Dr. Paziotopoulos highlights key compounds for longevity, emphasizing the essential role of vitamin D in overall health and its importance in cancer prevention. Dr. Paziotopoulos is a distinguished physician and researcher with a deep commitment to advancing the field of longevity and personalized medicine. With a background in both traditional medicine and cutting-edge technology, he has become a thought leader in the integration of artificial intelligence into health monitoring systems. His expertise encompasses a wide range of health topics, including the development of innovative health protocols and the exploration of novel compounds that promote longevity. Dr. Paziotopoulos is particularly passionate about the role of vitamin D in health, as well as the importance of water filtration and gut health. His forward-thinking approach emphasizes the need for data-driven solutions in healthcare, making him a pivotal figure in the future of age-reversal medicine and functional health. Follow him on Instagram : https://www.instagram.com/alexpazio/ Timestamps 02:57 The Journey to Medicine and Longevity 06:11 Medical Maintenance Engineering: A New Approach 09:05 Imaging and AI in Health Monitoring 11:59 The Role of Supplements in Longevity 18:03 The Importance of Compliance in Health Programs 21:01 Exploring Key Compounds for Longevity 23:59 The Benefits of Natural Foods vs. Supplements 26:57 Vitamin D: The Essential Hormone for Health 31:04 Vitamin D and Cancer Prevention 32:41 Exploring Methylene Blue 34:32 The Importance of Water Filtration 40:53 Patient Management and Protocol Development 52:33 Age-Reversal Medicine and Future Therapies 01:01:04 The Future of Medical Maintenance Engineering 01:03:43 The Future of Data-Driven Medicine 01:12:27 Understanding Omics and Personalized Health 01:19:24 AI's Role in Longevity and Health Optimization 01:26:40 Innovations in Cancer Detection and Treatment

Dr. Lecia Sequist, an expert in lung cancer and early detection, and Dr. Jeff Yang, a renowned thoracic surgeon, join Chadi to unravel the complexities of early lung cancer detection. Together, they explore the nuances of lung cancer screening, including the challenges of overdiagnosis and managing false-negative and false-positive results. The discussion delves into cutting-edge advancements like multi-cancer early detection tests, current patient screening eligibility criteria, and the critical factors contributing to low screening rates, such as accessibility barriers. They end on a note to raise awareness about the importance of lung cancer screening, emphasizing its safety, simplicity, and potential to save lives. Check out Chadi's website for all Healthcare Unfiltered episodes and other content. www.chadinabhan.com/ Watch all Healthcare Unfiltered episodes on YouTube. www.youtube.com/channel/UCjiJPTpIJdIiukcq0UaMFsA

In today's episode, I reveal the top health trends of 2025 that you can't afford to miss.   What We Discuss: 2025 Trends in Health ... 01:15 GLP1s: Managing body composition with emerging variations ... 01:30 Importance of lifestyle factors such as diet and exercise alongside GLP1s ... 03:45 Home Testing Innovations ... 05:05 Theriom's Aristotle Test and upcoming microbiome test ... 05:25 MI Screen: Non-invasive mitochondrial function test ... 07:40 True Diagnostic: The Harmony Test for aging ... 09:00 Syphox: Comprehensive blood analysis innovation ... 10:45 Vaitrakt: Affordable gut microbiome test ... 11:35 Prodrome Science Test: Practitioner guided health insights ... 13:20 Early Cancer Detection Advances ... 15:00 Auria Test: Tear-based breast cancer detection ... 16:50 QT Scan: Imaging dense breasts non-invasively ... 18:35 Cardiovision Care: Predictive cardiovascular disease test ... 20:10 Emerging Technologies in Peptides and Bioregulators ... 21:45 Enhanced bioavailability through skin delivery ... 22:00 Addressing past traumas and experiences for holistic health ... 27:25 Closing Remarks and Teasers for Future Episodes ... 31:30     Made Possible By Our Amazing Sponsor: Mitopure from Timeline: Improve your cellular health by taking Mitopure in its simplest form with two vegan softgels daily for the recommended dose of Urolithin A (500mg of Mitopure). Visit timeline.com/nat10 for 10% off. That's timeline.com/nat10.     Nat's Links: YouTube Channel Join My Membership Community Sign up for My Newsletter  Instagram  Facebook Group  

In today's episode, you'll get to explore the world of early cancer detection with Dr. Azra Raza, a pioneering oncologist and professor of medicine. We discuss the anxiety-inducing issues surrounding current cancer screening methods like mammograms and colonoscopies and examine advanced alternatives such as GRAIL and Cologuard. Dr. Raza also shares her groundbreaking work in detecting "The First Cell" and explores the potential of biomarkers and wearable devices for early detection (check out her fascinating book on this topic for more invaluable information!). In a deeply personal segment, Dr. Raza opens up about her late husband's battle with leukemia and how it shaped her understanding of cancer. We'll also discuss the flaws in the current cancer research model, the financial struggles for innovative scientists, and the urgent need for better funding to accelerate progress. Dr. Azra Raza is the Chan Soon-Shiong Professor of Medicine and Clinical Director of The Edward P. Evans Foundation MDS Center at Columbia University in New York. A practicing oncologist seeing 30–40 cancer patients weekly, she directs a basic cancer research lab with hundreds of original publications in high-profile journals. Her life is dedicated to the prevention of all chronic diseases, including cancer, by early detection. She worked with President Clinton, designing breakthrough developments in science and technology, and with President Joe Biden for the Cancer Moonshot initiative. Her latest book is a national bestseller and has been translated into nine languages. Dr. Raza is now involved in First Cell Therapeutics, developing a specific antibody to target and remove the tumor macrophage hybrid cells that act as The First Cell giving rise to cancer.  Full show notes: https://bengreenfieldlife.com/firstcell Episode Sponsors: Aires Tech: Aires Tech is offering you a 30% discount at airestech.com/ben by using code BEN30. Wild Health: Get 20% off with code BEN at wildhealth.com/ben. FUM: Head to tryfum.com/BEN and use code BEN to get a free gift with your Journey Pack! Vivobarefoot: You can purchase yours today with an exclusive 20% discount by going to vivobarefoot.com/bengreenfield and using code BENG20. MOSH: Head to moshlife.com/BEN to save 20% off plus FREE shipping on either the Best Sellers Trial Pack or the new Plant-Based Trial Pack.See omnystudio.com/listener for privacy information.

On Passion Struck, John is joined by Michael Marquardt, former Chair of the American Cancer Society and CEO of Epi-One, to explore groundbreaking breakthroughs in early cancer detection. The two dive deep into how epigenetic signals in the DNA molecule are revolutionizing how we diagnose cancer, offering hope for earlier and more effective treatments. Don't miss this insightful conversation on the future of cancer detection!His personal experiences with cancer, including the loss of his first wife, have driven his dedication to revolutionizing cancer detection and treatment. The episode shed light on the advancements in cancer research and the critical role of early detection in improving outcomes for cancer patients.Full show notes and resources can be found here: https://passionstruck.com/michael-marquardt-breakthroughs-cancer-detection/SponsorsBabbel is the new way to learn a foreign language. The comprehensive learning system combines effective education methods with state-of-the-art technology! Right now, get SIXTY percent off your Babbel subscription—but only for our listeners, at Babbel dot com slash PASSION.Stop hair loss before it's gone for good. Hims has everything you need to regrow hair. Start your free online visit today at “Hims dot com slash PASSIONSTRUCK.”Quince brings luxury products like Mongolian Cashmere, Italian Leather, Turkish Cotton and Washable Silk to everyone at radically low prices. Go to “Quince dot com slash PASSION” for free shipping on your order and 365-day returns.--► For information about advertisers and promo codes, go to:https://passionstruck.com/deals/JUST $0.99 FOR A LIMITED TIMEOrder a copy of my book, "Passion Struck: Twelve Powerful Principles to Unlock Your Purpose and Ignite Your Most Intentional Life," today!  Recognized as a 2024 must-read by the Next Big Idea Club, the book has won the Business Minds Best Book Award, the Eric Hoffer Award, the International Book Awards for Best Non-Fiction, the 2024 Melanie P. Smith Reader's Choice Contest by Connections eMagazine, and the Non-Fiction Book Awards Gold Medal. Don't miss the opportunity to transform your life with these powerful principles!In this episode, you will learn:The American Cancer Society has funded grants for 50 young researchers who have gone on to win the Nobel Prize.The American Cancer Society focuses on three pillars: research, patient support, and advocacy.Sedentary lifestyle and Western diets are contributing factors to the rise in cancer cases.EpiOne, a biotech startup, is pioneering early cancer detection through epigenetic signals on the DNA molecule.Early detection is crucial in improving cancer survival rates and treatment outcomes.EpiOne's technology can detect cancer signals at stage zero, allowing for early intervention and treatment.All Things Michael Marquardt: https://marquardtglobal.com/Catch More of Passion StruckCan't miss my episode withJulie Fleshman on How PanCAN Is Raising the Pancreatic Cancer Survival RateListen to my interview withDr. Lynn Matrisian on the Frontlines of Pancreatic Cancer – Education, Awareness, and ProgressWatch my episode with Bill Potts on Beat Cancer by Being Your Own Best AdvocateCatch my interview with Dr. Michael Pishvaian on Why Hope Is the Key to Fighting Pancreatic CancerLike this show? Please leave us a review here-- even one sentence helps! Consider including your Twitter or Instagram handle so we can thank you personally!